Teva and Fosun Pharma Join Forces to Advance Cancer Therapy
Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical have announced a major strategic alliance aimed at fast-tracking the development of a promising new cancer therapy.
The collaboration will centre around TEV-56278, Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy, which is currently in phase 1 clinical development for several hard-to-treat cancers, including melanoma.
The partnership marks a significant milestone in the global clinical journey of TEV-56278, with both companies expressing a shared commitment to accelerating data generation and expanding therapeutic reach.
This cutting-edge biologic therapy is engineered to selectively target PD-1-expressing T cells in the tumour microenvironment, enhancing the immune system’s ability to fight cancer while reducing the risk of harmful systemic side effects.
According to Teva, preclinical studies have already shown encouraging results, including tumour regression, increased infiltration of T cells into tumours, and the development of durable immune memory.
TEV-56278 is being explored both as a standalone treatment and in combination with Merck & Co.’s Keytruda (pembrolizumab), one of the most widely used immunotherapies in oncology today.
Commenting on the development, the Executive Vice President of Teva Global Research and Development and Chief Medical Officer stated that their partnership with Fosun Pharma in the development of TEV-56278 – an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers – is the latest step in their mission to accelerate their pipeline and bring forward transformative treatments.
What’s more, they added that this collaboration allows them to leverage the complementary strengths of both organisations to benefit patients around the world.
Under the terms of the agreement, Fosun Pharma has secured exclusive rights to develop, manufacture, and commercialise TEV-56278 in mainland China, Hong Kong SAR, Macau SAR, Taiwan, and select Southeast Asian countries.
Teva will retain all development and commercialisation rights outside of these regions, positioning the deal as a strategic regional alliance with global ambitions. Financial terms of the agreement remain undisclosed.
Fosun Pharma’s Executive President and CEO of the Global R&D Center also underscored the synergy of the partnership, commenting that this collaboration brings together Teva’s strength in developing innovative therapies with Fosun Pharma’s deep oncology experience and commercial infrastructure in China. Together, they are well-positioned to accelerate the delivery of this novel immunotherapy to patients in need.
As cancer remains one of the leading causes of death worldwide, this partnership signals a timely and much-needed push toward more precise, powerful, and safer immunotherapeutic options. With both companies firmly aligned in their vision, the advancement of TEV-56278 could represent a new frontier in the global fight against cancer.
Conclusion
The strategic partnership between Teva and Fosun Pharma stands as a powerful example of cross-border collaboration in oncology innovation.
By combining Teva’s advanced biologic platform with Fosun Pharma’s regional development and commercial strengths, TEV-56278 has the potential to emerge as a globally impactful cancer therapy.
As clinical trials progress and data accumulate, all eyes will be on this novel anti-PD1-IL2 ATTENUKINE therapy as it charts its course through the future of cancer care.
News Credits: Teva and Fosun Pharma partner on early-stage oncology drug
Things you may also like:
- Approved Bladder Cancer Treatment: UroGen’s Zusduri Offers New Hope for Patients
- eXmoor Pharma and Signadori Bio Forge Alliance to Advance Cutting-Edge Cell Therapy
- From Waste to Wonder: How Myco is Reinventing the Food Chain